NI201300007A - Un nuevo conjugado de granulocito colonia - estimulante factor (g -csf) con polietileno glicol. - Google Patents

Un nuevo conjugado de granulocito colonia - estimulante factor (g -csf) con polietileno glicol.

Info

Publication number
NI201300007A
NI201300007A NI201300007A NI201300007A NI201300007A NI 201300007 A NI201300007 A NI 201300007A NI 201300007 A NI201300007 A NI 201300007A NI 201300007 A NI201300007 A NI 201300007A NI 201300007 A NI201300007 A NI 201300007A
Authority
NI
Nicaragua
Prior art keywords
csf
stimulating factor
conjugate
granulocite
cologne
Prior art date
Application number
NI201300007A
Other languages
English (en)
Inventor
Veniaminovna Chernovskaya Tatyana
Alexandrovich Denisov Lev
Valentinovich Morozov Dmitriy
Georgievna Rudenko Elena
Leonidovna Morozova Elena
Original Assignee
Closed Join Stock Company Biocad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201300007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Closed Join Stock Company Biocad filed Critical Closed Join Stock Company Biocad
Publication of NI201300007A publication Critical patent/NI201300007A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona a farmacéuticos y medicinas, específicamente, a un nuevo conjugado fisiológicamente de granulocita colonia estimulante factor (G -CSF) con la fórmula general: (I) Donde: n - intergers de 681 a 1,000; m - interger 4; NªH - G - CSF - Natural o recombinante polipéptido, teniendo actividad de G - CSF. La invención También está relacionada a medicinas conteniendo el conjugado reclamado de fórmula (1), composiciones farmacéuticas, el uso de conjugado de fórmula (1) para drogas y medicinas con granulocita colonia estimulante factor como un ingrediente activo, se aproxima a prevenir y/o tratar la neutropenia, el contenedor que contiene la composición farmacéutica.
NI201300007A 2010-08-13 2013-01-18 Un nuevo conjugado de granulocito colonia - estimulante factor (g -csf) con polietileno glicol. NI201300007A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (ru) 2010-08-13 2010-08-13 Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе

Publications (1)

Publication Number Publication Date
NI201300007A true NI201300007A (es) 2014-05-26

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300007A NI201300007A (es) 2010-08-13 2013-01-18 Un nuevo conjugado de granulocito colonia - estimulante factor (g -csf) con polietileno glicol.

Country Status (17)

Country Link
KR (1) KR101549457B1 (es)
CN (1) CN103140499B (es)
CL (1) CL2013000400A1 (es)
CO (1) CO6670557A2 (es)
CR (1) CR20130020A (es)
CU (1) CU24139B1 (es)
DO (1) DOP2013000003A (es)
EA (1) EA019043B1 (es)
EC (1) ECSP13012399A (es)
MA (1) MA34525B1 (es)
MY (1) MY160732A (es)
NI (1) NI201300007A (es)
PE (1) PE20131085A1 (es)
RS (1) RS20130094A1 (es)
RU (1) RU2446173C1 (es)
SG (1) SG187572A1 (es)
WO (1) WO2012021088A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
ES2691493T3 (es) 2012-06-07 2018-11-27 Childrens Hospital Los Angeles Métodos para tratar la neutropenia usando agonistas retinoides
CN103908427B (zh) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法
RU2535002C2 (ru) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
AU2015219038B2 (en) 2014-02-18 2018-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
JP6742300B2 (ja) * 2014-07-14 2020-08-19 ジェンノヴァ バイオファーマシューティカルズ リミテッド rHu−GCSFの精製のための新規プロセス
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
BR112022018501A2 (pt) * 2020-03-17 2022-10-25 Drugrecure Aps Formulação líquida de gm-csf para inalação

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (ko) * 2003-03-21 2004-10-01 한미약품 주식회사 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법
RU2278870C2 (ru) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения, и иммунобиологическое средство на его основе
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
JP2009541333A (ja) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ

Also Published As

Publication number Publication date
CU24139B1 (es) 2015-12-23
EA201101035A1 (ru) 2012-02-28
RU2446173C1 (ru) 2012-03-27
CO6670557A2 (es) 2013-05-15
PE20131085A1 (es) 2013-10-10
DOP2013000003A (es) 2013-07-31
CN103140499A (zh) 2013-06-05
MA34525B1 (fr) 2013-09-02
KR101549457B1 (ko) 2015-09-02
SG187572A1 (en) 2013-03-28
MY160732A (en) 2017-03-15
WO2012021088A1 (en) 2012-02-16
ECSP13012399A (es) 2013-05-31
KR20130043167A (ko) 2013-04-29
EA019043B1 (ru) 2013-12-30
CN103140499B (zh) 2014-12-17
CL2013000400A1 (es) 2013-07-26
RS20130094A1 (en) 2013-08-30
CR20130020A (es) 2013-02-20
CU20130012A7 (es) 2013-04-19

Similar Documents

Publication Publication Date Title
NI201300007A (es) Un nuevo conjugado de granulocito colonia - estimulante factor (g -csf) con polietileno glicol.
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
BR112013003045A2 (pt) composto e composição farmacêutica e respectivos usos, recipiente estéril e método para preparar composição farmacêutica para administração
BR112013031268A2 (pt) "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição".
TN2015000187A1 (en) Triazolopyrazine
TR201904614T4 (tr) Novel pyrazole derivative.
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
EA201600366A1 (ru) Производные бензимидазол-пролина
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
MX2014013095A (es) Forma de dosificacion farmaceutica termoconformada, resistente al uso indebido, que contiene zinc.
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR112012017310A2 (pt) derivados de triazol substituídos como moduladores de gama secretase
MX345238B (es) (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112012024712A2 (pt) antagonistas do receptor vaniloide trpv1 com uma porção bicíclica
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
BR112014015630A8 (pt) fluorometil-5,6-di-hidro-4h-[1,3]oxazinas, seus usos, e composição farmacêutica
EA201401309A1 (ru) Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
BR112013006651A2 (pt) composição e cocristal de aprepitante l-prolina
CY1115600T1 (el) Πιπεραζινες ως ανθελονοσιακοι παραγοντες
MX369508B (es) Derivados de tio novedosos que tienen lactamas como potentes inhibidores de hdac y sus usos como medicamentos.
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite